17,261 trials
Epilepsy
Primary: Percentage of Responders During the Maintenance Phase — 44.4; 34.2; 55.6; 65.8 Percentage of Participants
Breast Cancer · Cardiac Toxicity
Primary: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment — 0 participants
Cervical Strain
Primary: Pain
Lung Cancer
Primary: Survival Rate at 6-months Chemotherapy-progression-free (CP-free) — 55 percentage of participants
Sclerotic Graft Versus Host Disease · Imatinib Mesylate
Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline
Brain and Central Nervous System Tumors
Primary: Safety of Treatment — 1; 1; 5; 1 participants
Pain
Primary: Efficacy Rate (Percentage) of Patient's Impression — 64.1; 25.9 percentage of participants — p=<0.0001
Heart Failure · Growth Hormone Deficiency · Ischemic Heart Disease
Primary: Peak VO2 — 14.5; 12.9 ml/kg/min
Type 2 Diabetes
Primary: Systolic Blood Pressure, Change From Baseline to End of Treatment — -0.5; 9.2 mmHg
Melanoma (Skin)
Primary: Number of Participants With Partial Response — 1 participants
Osteoporosis · Postmenopausal Osteoporosis
Primary: Least Squares Mean Percent Change From Baseline To Month 12 in Lumbar Spine Areal Bone Mineral Density (BMD) — -0.36; -0.67; -0.52; -0.53 percent change — p=0.012
Lung Cancer
Primary: Interleukin Levels at 24 Hours — 245; 269; 11.3; 14.8 pg/ml — p=0.39
Leukemia · Lymphocytic · Chronic
Primary: Response Rate — 0; 1; 3; 11 Participants
Parkinson Disease
Primary: Gait Speed — 8.35; 8.41; 25.84; 8.80 seconds
Thymoma · Thymic Carcinoma · Thymic Carcinoid
Primary: Objective Response Rate (Partial Response (PR)+Complete Response (CR)) to IMC-A12 Monotherapy in Patients With Advanced or Recurrent Thymoma or Thymic Carcinoma. — 0; 0…